Second Novartis Trial Conductor In Japan Reports Data Manipulation
This article was originally published in PharmAsia News
A second Japan university has reported manipulation of data involved in clinical trials of a Novartis Pharma blood pressure drug, leading to a retraction of a published study of favorable results from the tests.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.